Abstract:Wen-Xia Hu, Jing-Cui Peng, Yun Wang, Hao Jin, Nan Geng Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050012, People's Republic of China Correspondence: Nan Geng, Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, 12 Jian-Kang Road, Shijiazhuang, 050012, People's Republic of China, Tel +86 13933852787, Email Objective: This study was to investigate the efficacy and safety of gefitinib plus anlotinib for patients with EGFR positive advanced non-small cell lung cancer (NSCLC) in a first-line setting. Methods: A total of 36 patients with previously-untreated EGFR positive advanced NSCLC were included in this study retrospectively. All patients were administered with gefitinib plus anlotinib combination therapy. The efficacy of the patients was evaluated with the change of target lesion using imaging evidence according to RECIST 1.1 criteria and all the patients were followed up regularly. Adverse reactions were collected and documented during the combination administration. Univariate analysis according to the baseline characteristic subgroup was implemented using Log rank test and multivariate analysis was adjusted by Cox regression analysis. Results: All the 36 patients included in our study were available for efficacy and safety analysis. Best overall response of the patients during gefitinib plus anlotinib administration suggested that partial response was observed in 30 patients, stable disease was noted in five patients, and progressive disease was found in one patient, which yielded an objective response rate (ORR) of 83.3% (95% CI=67.2– 93.6%) and a disease control rate (DCR) of 97.2% (95% CI=85.5– 99.9%). Prognostic data indicated that the median progression-free survival (PFS) of the 36 patients with NSCLC was 15.2 months (95% CI=8.15– 22.26). Furthermore, the median overall survival (OS) of the 36 patients was 35.9 months (95% CI=22.77– 49.03). Additionally, the most common adverse reactions of the patients with NSCLC were diarrhea (63.9%), fatigue (58.3%), hypertension (50.0%), rash (44.4%), and nausea and vomiting (41.7%). Furthermore, ECOG performance status was associated with PFS of gefitinib plus anlotinib combination therapy in baseline characteristic subgroup analysis. Conclusion: Gefitinib plus anlotinib regimen demonstrated encouraging efficacy and an acceptable safety profile for patients with previously untreated EGFR positive NSCLC preliminarily. The conclusion should be validated in prospective clinical trials subsequently. Keywords: non-small cell lung cancer, EGFR mutation, anlotinib, gefitinib, efficacy, safety As the second most common solid tumor and the leading cause of cancer-related death all over the world, lung cancer was observed of approximately 815,000 new cases and 715,000 deaths in China each year. 1 Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer. 2 Patients with epidermal growth factor receptor (EGFR) positive mutation were reported to be of almost 40% among all NSCLC in China. 3 As a result, it is estimated that there are approximately 277,000 new cases of NSCLC with EGFR positive mutation in China annually. To our knowledge, pivotal trials established EGFR tyrosine kinase inhibitor (TKI) therapy as the standard of care for patients with EGFR positive NSCLC since 2004. 4 Amazingly, recent years had witnessed remarkable achievements regarding the targeted drugs for patients with EGFR mutation, thus rendering NSCLC with a positive EGFR mutation the most successful cancer in precision medicine. 5 Gefitinib, erlotinib, afatinib, dacomitinib, and Osimertinib were efficacious in clinical practice as the first-line therapy for patients with EGFR mutation NSCLC currently. 6 Unfortunately, with regard to the first-generation EGFR TKIs (gefitinib, erlotinib, and Icotinib) in China, although 60–80% of the patients with EGFR positive mutation had responses following the administration with these drugs, the median progression-free survival (PFS) was still dismal (approximately 1 year) owing to the acquired therapeutic resistance. 7 Additionally, it should be noted that a third-generation EGFR TKI (Osimertinib) was a superior first-line treatment according to the FLAURA study. 8 However, there was no standard targeted drug therapy after Osimertinib progression and the optimized therapy strategy across multiple treatment lines remained unknown. 9 Consequently, it was necessary to investigate the efficacious first-generation EGFR TKI-based regimens for delaying the progression in the first-line setting urgently. Resistance to EGFR TKIs was always associated with elevated vascular endothelial -Abstract Truncated-

Role of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma.

EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

Detection of EGFR Mutations in Plasma Circulating Tumour DNA As a Selection Criterion for First-Line Gefitinib Treatment in Patients with Advanced Lung Adenocarcinoma (BENEFIT): a Phase 2, Single-Arm, Multicentre Clinical Trial

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Critical Appraisal of the Role of Gefitinib in the Management of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment A cohort study

Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in Egfr-Mutation- Positive Non-Small-Cell Lung Cancer after Progression on First-Line Gefitinib (impress): A Phase 3 Randomised Trial

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study

A Phase I/II Clinical Trial on the Efficacy and Safety of NKT Cells Combined with Gefitinib for Advanced EGFR-mutated Non-Small-cell Lung Cancer

Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.

Effect of Gefitinib Challenge to Initial Treatment with Non-Small Cell Lung Cancer

Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

Combination therapy with afatinib and bevacizumab in an <i>EGFR</i>-mutated non-small cell lung cancer patient with acquired ERBB2 amplification A case report

Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced <i>EGFR</i> L858R NSCLC.

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.

Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma